- Expands Beckman Coulter's Worldwide Position in Clinical Chemistry
- Complementary Market Positions and Product Portfolios in Chemistry and Automation Broaden Global Opportunity, Increase Customer Choice
- Penetration of Beckman Coulter's Immunoassay Products into Olympus' Installed Chemistry Base Supports Continued Above-Market Growth
- Transaction Expected to be Accretive to Non-GAAP Earnings Per Share in 2010
ORANGE COUNTY, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer, manufacturer, and marketer of products that simplify, automate, and innovate complex biomedical tests, and Olympus Corporation, a Tokyo-headquartered precision technology leader, creating innovative opto-digital solutions in healthcare, life science and consumer electronics products, announced today that they have entered into a definitive agreement under which Beckman Coulter will acquire the diagnostic systems portion of Olympus' Life Sciences business for 77.45 billion yen, or approximately USD $800 million.
This acquisition will broaden Beckman Coulter's Chemistry offering, establishing a leadership position with particular strength in larger hospital laboratories. In addition, the transaction will extend our broad chemistry customer base representing a valuable new customer set for Beckman Coulter's Immunoassay products.
In 2010, the Olympus Diagnostics business is anticipated to increase Beckman Coulter's revenue by approximately $500 million on a full year basis and generate approximately $40 to $50 million in operating income (excluding FAS141R associated amortization). Beckma
|SOURCE Beckman Coulter, Inc.|
Copyright©2009 PR Newswire.
All rights reserved